Kornimate/medical-research-clean huggingface dataset:
autologous cd19 car t cells in relapsed or refractory b-cell lymphoma

Conditions: B-cell Lymphoma

Summary: this is a single arm, open-label, one center, dose escalation clinical study to determine the safety and efficacy of infusion of autologous t cells expressing cd19-redirected chimeric antigen receptor (cd19 car t) in adult patients with relapsed or refractory cd19 positive b-cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. cd19+ b cell lymphoma,verified by ihc or flow cytometry. 2. a prior history of at least two standard care of medication. 3. ineligible for allogeneic transplantation or relapsed after transplantation. 4. patients are 18 years older. 5. life expectancy \> 3months. 6. ecog ≤ 2. 7. satisfactory major organ functions: adequate heart function with lvef≥50%; pulse oximetry of ≥ 90%; cockcroft-gault creatinine clearance≥40 ml/min; alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤3uln; bilirubin ≤2.0 mg/dl . 8. blood: hgb ≥ 80 g/l, anc ≥ 1×10\^9/l, plt ≥ 50×10\^9/l. 9. women of reproductive potential must have a negative pregnancy test. male and female of reproductive potential must agree to use birth control during the study and one year post study. 10. measurable tumors. exclusion criteria: 1. using immunosuppressive drugs or systemic steroids within one week of enrollment. 2. active infection. 3. hiv positive. 4. active hepatitis b virus infection or hepatitis c virus infection. 5. breastfeeding or pregnant women. 6. patients refuse to practice birth control during study and one year post study. 7. patients with a prior history of other malignances will be excluded from this study, but patients who have been cured from skin basal cell carcinoma or cervical cancer, or who have had their tumors removed by surgical resection but without further therapies and have more than 5 years of progression-free survival, can be included into the study. 8. currently enrolled in other study. 9. patients, in the opinion of investigators, may not be eligible or are not able to comply with the study.
comparing nd:yag laser and sequential double frequency yag-nd:yag laser iridotomy

Conditions: Angle Closure Glaucoma

Summary: no single type of laser or set of laser parameters is appropriate for all type of irides. pure nd:yag laser iridotomy is very effective in the light color irides. it was considered as the gold standard for iridotomy. it, however, is less effective and causes some complication such as iris hemorrhage especially in patients with dark iris.

by using the double frequency yag to make the initial bore and the nd:yag laser to complete the perforation, the technique should be able to effectively combine most of the advantages of both lasers whilst avoiding their disadvantages. it is possibly the ideal iridotomy technique to use in the asian irides. the investigators aim to study the energy use for laser iridotomy comparing between the two techniques as well as objectively measure the variables associated with complications.

Eligibility criteria:
inclusion criteria: * patient in need to have a laser iridotomy * primary angle closure glaucoma or * primary angle closure or * primary angle closure suspect (needed repeated pupil dilation) or * fellow eyes of acute angle closure crisis, and * age of at least 18 years, and * dark iris patients (only black and dark brown color) exclusion criteria: * eye with acute angle closure crisis * active conjunctiva or corneal infection or inflammation * active anterior uveitis * history of any prior laser treatment * history intraocular surgery * eye with corneal scar * corneal haziness obscure iridotomy site * endothelial cell count less than 1000 cells/mm2 (pre-laser) * iris color other than black or dark brown * inability to sit at the slit lamp to have laser done

Keywords: iridotomy
effectiveness and safety of atelocollagen in the management of chronic non-specific low back pain

Conditions: Low Back Pain

Summary: the purpose of this study was to evaluate the effectiveness and safety of atelocollagen in the management of chronic low back pain with sarcopenia due to degenerative changes.

patients with chronic low back pain are enrolled and divided into group a (atelocollagen) and group b (control) through randomization after obtaining informed consent. investigators record tender points for the multifidus, erector spinae, and quadratus lumborum muscles by physical examination. investigators evaluate each muscle using ultrasound according to the assignment of each group, and apply atelocollagen mixture (atelocollagen 3 ml + 1% lidocaine 3 ml) or local anesthetics only (normal saline 3 ml + 1% lidocaine 3 ml) to each muscle on both sides. the subject of the study performs a total of 3 injections at intervals of 2 weeks, and each measurement variable is collected by visiting 4 weeks and 12 weeks after the last injection. changing medications or additive interventions are not allowed before 4 weeks after last injection. only acetaminophen is allowed as a rescue drug.

Eligibility criteria:
inclusion criteria: - non-specific low back pain with persistent paraspinal tenderness of nrs 4 or higher despite conservative treatment (including physical therapy, exercise therapy, oral drug administration, and epidural block) for at least 3 months. adults 19 years of age or older exclusion criteria: - systemic or local infection coagulopathy patients whose structure is difficult to confirm on ultrasound due to significant deformity of the lumbar spine neoplasm of spine cognitive disorder patients with hypersensitivity to local anesthetics or amide-based local anesthetics patients those who are allergic to or sensitive to atelocollagen ingredients or pork women who are pregnant, lactating, or planning to become pregnant during the clinical period, or women of childbearing age who are not using available contraceptive methods those who participated in other clinical trials within 30 days prior to screening or 5 times the half-life of the investigational drug in the clinical trial in which they participated, whichever is longer, whichever is longer patients with serious systemic diseases
effectiveness, safety and immunogenicity of gsk biologicals' hpv vaccine gsk580299 (cervarix) administered in healthy adolescents

Conditions: Infections, Papillomavirus

Summary: genital infections with oncogenic human papillomaviruses (hpv) are common in both men and women. the most important disease associated with oncogenic hpv infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. the current study is designed to evaluate the overall impact of hpv immunization in adolescents 12-15 years of age.


Eligibility criteria:
inclusion criteria: * study participants who the investigator or delegate believes that they and/or their parents/legally acceptable representative can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study. * a male or female between, and including, 12 and 15 years of age at the time of the first vaccination. a written informed assent must be obtained from all study participants prior to enrolment. in addition, a written informed consent must be obtained from the study participants' parent or legally acceptable representative. note: as according to the finnish law legal age of consent is 15 years, a written informed consent form can be obtained from study participants aged 15 years old and their parent(s)/legally acceptable representative(s) will receive a letter informing them of their child participation to the study. * healthy male and female study participants as established by medical history before entering into the study. if needed, a history-directed clinical examination will be performed by the investigator or delegate (e.g. study nurse). * study participants must not be pregnant. absence of pregnancy should be verified (e.g. urine pregnancy test) as per investigator's or delegate's clinical judgement. * if the study participant is female, she must be of non-childbearing potential, i.e. be abstinent, have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal or pre-menarcheal, or if she is of childbearing potential, she must use adequate contraception for 30 days prior to vaccination and continue for 2 months after completion of the vaccination series. exclusion criteria: * previous vaccination against hpv or hepatitis b virus. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccines. * acute disease at the time of enrolment. (acute disease is defined as the presence of a moderate or severe illness with or without fever. all vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. oral temperature \<37.5°c (99.5°f) / axillary temperature \<37.5°c (99.5°f) / rectal temperature \<38°c (100.4°f).) * pregnant or lactating female.

Keywords: hpv vaccine healthy adolescents cervical cancer safety immunogenicity cervarix
lung health after tuberculosis: clinical and functional assessment in post pulmonary tuberculosis egyptian patients.

Conditions: Pulmonary Tuberculoses; Pulmonary Function; Newborn, Abnormal

Summary: some of pulmonary tuberculous patients who completed their medication course experience lung function impairment

some of pulmonary tuberculous patients who completed their medication course experience lung function impairment which may influence their quality of life. however, the pattern and nature of post-tuberculosis lung impairment is still not identified. thus, the aim of this study was to determine the type and degree of lung physiology changes in previously treated tuberculous patients which latter may affect their quality of life; thus helping clinicians for early diagnosis of lung impairment, especially in tuberculous endemic areas.

Eligibility criteria:
inclusion criteria: * patient completed an outpatient course of standard first line anti-tuberculosis therapy and declared as cured exclusion criteria: * smoker (to avoid spirometry biases). * extrapulmonary tuberculosis cases * multidrug resistant tuberculosis * known contraindications to spirometry testing * individuals with chest wall deformities or neuromuscular diseases * patients who failed to achieve acceptability and reproducibility criteria of the spirometry test * defaulter cases or irregular treatment, * known coexisting chronic lung disease as history of asthma or interstitial lung diseases * a history of illicit drug use * patients with comorbidities: renal and hepatic insufficiency, heart diseases and metabolic disorders.

Keywords: pulmonary tuberculosis spirometry pulmonary function
role of flavanols in exercise and aging

Conditions: Aging

Summary: it has well known that diets rich in fruits, vegetables and cocoa products are associated with positive health benefits and these positive effects have been shown to be due to compounds they contain called flavanols. flavanols have been shown to exert their positive effects by indirectly increasing nitric oxide (no) bioavailability. no is a potent vasodilator that is believed to play a role in increasing blood flow to active muscle during exercise. this regulatory process is impaired with healthy aging. the underlying premise to this study is that if no bioavailability can be increased following flavanol ingestion, will there be a restoration of blood flow during exercise in older individuals? accordingly, the first part of this research project will compare the acute vascular effects of flavanol ingestion between a young and old group. the investigators have hypothesized that both groups will show an improvement in blood flow to active muscle during exercise, though the magnitude of the change will be greater in the older group. the second part of this project will look at the effects of 4 weeks of daily flavanol ingestion in the old group. the investigators hypothesize that subjects will demonstrate an improvement in blood flow to active muscle during exercise after the 4 week intervention and that the magnitude of the change will be greater than the acute effects. findings from this proposal will provide evidence for the efficacy of flavanols to be used (as a simple and safe lifestyle intervention) to reverse or combat impaired blood flow regulation in older individuals.


Eligibility criteria:
inclusion criteria: * males and females between 18 - 30 years old * males and females between 60 - 80 years old exclusion criteria: * cardiovascular and/or microvascular disease * blood clotting disorder * pregnant lady * current smoker (or regularly smoked within last year) * a history of an adverse reaction to cold * taking medications known to effect the autonomic nervous system

Keywords: exercise blood flow nitric oxide aging antioxidant flavanol young (18-30 yrs) aging (60 - 80 yrs)
short running head obesity in rectal cancer patients

Conditions: Rectal Cancer

Summary: there is a controversy regarding the effect of the two body mass index (bmi) extremes on the oncological outcome of rectal cancer. the obesity paradox appears to exist in rectal cancer patients treated with ncrt and surgery, as it was associated with significantly higher rates of pathological complete response and r0 resection. underweight patients were at higher risk for anastomotic leak and r1 resection.

background: obesity and underweight are associated with increased risk of postoperative morbidity in colorectal cancer patients undergoing surgery. there is a controversy regarding the effect of the two body mass index (bmi) extremes on the oncological outcome of rectal cancer. objective: the aim of this study was to evaluate the effect of bmi on short- and long-term oncological outcomes as well as postoperative complications in rectal cancer patients who received neoadjuvant chemoradiotherapy (ncrt) followed by surgery. setting: tertiary cancer center serving pediatric and adult patients in jordan and the middle east. patients: the medical records of patients with stage ii-iii rectal cancer who received ncrt followed by surgery during 2006 to 2018 were retrospectively reviewed. the patients were subdivided according to their bmi into less than 20 kg/m2 defined as underweight; between 20 to 30 kg/m2 defined as normal range weight, above 30 kg/m2 defined as obese. main outcome measures: disease-free survival (dfs), overall survival, pathological complete response (cr)

Eligibility criteria:
inclusion criteria: * patients who underwent rectal surgery at king hussein cancer center (khcc) from 2006 to 2018 were identified. those with locally advanced rectal cancer (stages ii and iii) who underwent ncrt followed by surgery with curative intent were included. exclusion criteria: * patients with early rectal cancer (stage i) who did not require ncrt and those who underwent rectal surgery as part of a staged or simultaneous approach for metastatic disease (stage iv) were excluded.

Keywords: oncology colorectal cancer surgery surgical oncology obesity
is intraperitoneal drainage necessary following distal pancreatectomy?

Conditions: Cyst of Pancreas; Pancreatectomy; Pancreas Neoplasm

Summary: the goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. this study aims to determine whether the omission of routine intraperitoneal drainage in the setting of reinforced staple technology is non-inferior to routine intraperitoneal drainage with respect to a composite post-operative complications of grade b or c postoperative pancreatic fistula (popf), readmission, or organ space surgical site infection following a distal pancreatectomy.

pancreatic resections are commonly performed across the united states, yet still represent one of the most morbid abdominal operations in the country, with postoperative mortality as high as 7.7%. distal pancreatectomy (dp) represents one of the most common approaches to pancreatic resection and is typically used for tumors of the pancreatic body or tail. this operation is known to have a high historic morbidity, with reports of overall morbidity between 12-52%. common complications include intraabdominal abscess and surgical site infection. postoperative pancreatic fistula (popf) represents the most common complication following partial pancreatic resection, with rates reported with rates as high as 30% in multiple large retrospective studies. multiple strategies to prevent postoperative pancreatic leak following distal pancreatectomy have been studied. one of the outstanding questions that remains is regarding the need for routine intraperitoneal drainage following dp, particularly since the advent of reinforced staple technology. this study aims to determine if intraperitoneal drainage is necessary following dp. this study will compare groups using a composite endpoint of complications.

Eligibility criteria:
inclusion criteria: * subjects must be undergoing a scheduled distal pancreatectomy (with or without concurrent splenectomy) * age ≥18 years * subjects must have the ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * patients \< 18 years old * patients who are pregnant * patients with a history of previous pancreatic surgery * patients with a history of prior gastric resection, gastric bypass or sleeve gastrectomy * patients with prior cystogastrostomy procedure * patients who have failed prior endoscopic intervention or ultrasound due to esophageal or other gastrointestinal stricture * patients with type 3 or type 4 paraesophageal hernia noted either on pre-operative imaging or intra-operatively * patients undergoing concurrent resection of organs other than the pancreas or spleen or gallbladder * patients who undergo oversewing of the pancreatic transection margin * patients with unexpected intraoperative bleeding or adhesive disease which deem it unsafe to proceed without an intraabdominal drain * patients who are unable to provide informed consent

Keywords: pancreatic neoplasm
s100a8 in serum and urine as a new biomarker in lupus nephritis

Conditions: S100A8; Serum; Urine; Biomarker; Lupus; Nephritis

Summary: this study aims to evaluate both serum and urine s100a8 as potential biomarkers for lupus nephritis (ln)

systemic lupus erythematosus (sle) is a systemic autoimmune/ inflammatory disease that can affect any organ of the human body. the molecular pathophysiology of sle remains largely unknown, but complex interactions of genetic factors, the environment, and hormones contribute to disease expression. clinical importance of s100 calcium-binding protein a8 protein (s100a8) as a biomarker in sle has been well-established. during an inflammatory reaction, neutrophils produce s100a8, a ca2+-binding protein that is part of the s100 family and is found in neutrophil extracellular traps. in addition to its primary role as a member of the s100a8/a9 heterodimer, s100a8 accumulates in various bodily compartments and functions as a damage-associated molecular pattern molecule upon release. it is a crucial regulator of inflammation and enhances the function of innate immune cells by interacting with members of the immunoglobulin superfamily of cell surface molecules, such as toll-like receptor 4 and the receptor of advanced glycation end products. serum s100a8 levels are linked with disease activity, glomerulonephritis, and anti-double-stranded dna (dsdna) antibodies (ab), according to increasing experimental and clinical data. healthy controls (hcs) had lower serum s100a8 levels. considering that elevated blood s100a8 levels are also seen in several inflammatory disorders such as inflammatory bowel disease and rheumatoid arthritis, it is unclear if this elevated level is adequate to serve as a biomarker specific to sle.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * both sexes. * patients with systemic lupus erythematosus (sle) * patients with sle and renal affection. sle diagnosis is based on the 1997 american college of rheumatology (acr) criteria or the 2012 systemic lupus international collaborating clinics (slicc) classification criteria. renal involvement (lupus nephritis) (ln) can be diagnosed by presence of proteinurea or elevated kidney function and can be confirmed by biopsy if present. exclusion criteria: * autoimmune diseases. * sjogren's syndrome. * rheumatoid arthritis. * systemic sclerosis. * taking other biologic disease-modifying anti-rheumatic drugs. * immunosuppressive drugs. * corticosteroid.
effects of topical vitamin k, vitamin k and retinol, and arnica on post-laser bruising

Conditions: Ecchymosis

Summary: the objective of this study is to assess the comparative utility of topical formulations in hastening the resolution of skin bruising. for each subject, four standard bruises of 7 mm diameter each were created on the bilateral upper inner arms, 5 cm apart, two per arm, using a 595-nm pulsed-dye laser. randomization was used to assign one topical agent (5% vitamin k, 1% vitamin k and 0.3% retinol, 20% arnica or white petrolatum) to exactly one bruise per subject, which was then treated under occlusion twice a day for 2 weeks. a dermatologist rated bruises in standardized photographs immediately after bruise creation and at week 2.


Eligibility criteria:
inclusion criteria: * age 20-60 * subjects are in good health. * subjects have willingness and the ability to understand and provide informed consent for participation in the study. exclusion criteria: * subjects who are currently using any anticoagulation therapy (warfarin, heparin, aspirin) * subjects who have a history of bleeding disorders. * subjects who are unable to understand the protocol or to give informed consent * subjects with mental illness * subjects who are pregnant or nursing. * subjects who have active systemic or local infection * subjects with systemic or local skin disease. * subjects with systemic illness.

Keywords: bruising topical 20% arnica
drug penetration into bone after repeated oral administration of debio 1450 to patients undergoing hip replacement surgery

Conditions: Bone Diseases, Infectious

Summary: debio 1450 is being developed for the treatment of staph (staphylococcal) infections. how fast and completely an antibiotic penetrates into bone is used to determine how effective it might be to treat infections related to bones or joints. since bone has fewer blood vessels than other tissue (for example lung tissue or the skin), drugs have a harder time getting into them. it is important to find out how much of the antibiotic can get into the bone to help patients with bone infections.


Eligibility criteria:
inclusion criteria: * meets protocol-specified criteria for qualification and contraception * is willing and able to comply with restrictions related to food, drink and medications * voluntarily consents to participate and provides written informed consent prior to any protocol-specific procedures exclusion criteria: * has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters * has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or well-being of the participant or study staff; 2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3. the analysis of results